



---

**Human gut microbiota-fermented asparagus powder  
protects human epithelial cells from injury and  
inflammation**

Journal:	<i>Food &amp; Function</i>
Manuscript ID	FO-ART-07-2024-003504.R1
Article Type:	Paper
Date Submitted by the Author:	15-Dec-2024
Complete List of Authors:	Rajakaruna, Sumudu; Wright State University, Department of Biochemistry and Molecular Biology Bandow, Brant; Wright State University, Department of Biochemistry and Molecular Biology Pérez-Burillo, Sergio; Wright State University, Department of Biochemistry and Molecular Biology Navajas-Porras, Beatriz; University of Granada, Department of Nutrition and Food Sciences Rufian-Henares, J.; University of Granada, Department of Nutrition and Food Sciences; University de Granada, Instituto de Investigación Biosanitaria ibs.GRANADA Cool, David ; Wright State University, Department of Pharmacology & Toxicology Cho, Kwang-Jin; Wright State University, Department of Biochemistry and Molecular Biology Paliy, Oleg; Wright State University, Department of Biochemistry and Molecular Biology

1 **Human gut microbiota-fermented asparagus powder protects human epithelial cells from injury**  
2 **and inflammation**

3

4 Sumudu RAJAKARUNA <sup>a</sup>, Brant BANDOW <sup>a</sup>, Sergio PÉREZ-BURILLO <sup>a</sup>, Beatriz NAVAJAS-  
5 PORRAS <sup>b</sup>, José Ángel RUFÍAN-HENARES <sup>b,c</sup>, David R. COOL <sup>d</sup>, Kwang-Jin CHO <sup>a</sup>, and Oleg  
6 PALIY <sup>a\*</sup>

7

8 <sup>a</sup> *Department of Biochemistry and Molecular Biology, Boonshoft School of Medicine, Wright State*  
9 *University, Dayton, Ohio, USA*

10 <sup>b</sup> *Department of Nutrition and Food Sciences, Instituto de Nutrición y Tecnología de los Alimentos,*  
11 *Centro de Investigación Biomédica, University of Granada, Granada, Spain*

12 <sup>c</sup> *Instituto de Investigación Biosanitaria ibs.GRANADA, University de Granada, Granada, Spain*

13 <sup>d</sup> *Department of Pharmacology & Toxicology, Boonshoft School of Medicine, Wright State University,*  
14 *Dayton, Ohio, USA*

15

16 \* Corresponding author. Address: 260 Diggs Laboratory, Wright State University, 3640 Colonel Glenn  
17 Hwy, Dayton OH 45435, USA. Email: oleg.paliy@wright.edu

18

19 Author emails:

20 rajakaruna.2@wright.edu

21 bandow.3@wright.edu

22 spburillo@gmail.com

23 beatriz.navajas@fisabio.es

24 jarufian@ugr.es

25 david.cool@wright.edu

26 kwang-jin.cho@wright.edu

27 oleg.paliy@wright.edu

28

**29 Abstract**

30 Dietary consumption of green asparagus has been associated with several health benefits. These  
31 beneficial properties are attributed to the presence of many bioactive compounds in asparagus, including  
32 saponins, phenolics, flavonoids, as well as dietary fiber mostly comprising fructans and inulins, which  
33 are prebiotics capable of supporting the growth of beneficial members of gut microbiota. In this study,  
34 we used the *in vitro* Human Gut Simulator system to assess the fermentation of oro-gastro-intestinally  
35 digested asparagus powder by the human gut microbiota. Microbial community composition differed  
36 between communities grown on the asparagus digest and on the Western diet derived medium.  
37 Asparagus supported beneficial *Ruminococcus* but also hydrogen sulfide producing members of  
38 Desulfovibrionaceae. Fermentation of asparagus released more antioxidants into the environment  
39 compared to the Western diet medium, and supernatant of asparagus-grown cultures protected cultured  
40 human epithelial cells against damage and inflammation. We thus showed that asparagus powder has a  
41 potential to be used as a functional food, offering protection against intestinal damage and inflammation  
42 – effects mediated by the gut microbiota.

43

44 **Keywords:** asparagus, gut microbiota, short-chain fatty acids, antioxidants, human microbiome

45

**46 Introduction**

47 Asparagus is a perennial herb that has been used as a vegetable since ancient times. Currently, over 200  
48 species of asparagus have been identified, out of which only *Asparagus officinalis* is cultivated as a  
49 commercial vegetable in over 60 countries <sup>1</sup>. China, Western Europe, North America, and Peru are the  
50 largest asparagus producers, while the USA is the largest importer (accounting for 92,000 tons in 2018)  
51 <sup>2</sup>. Fresh or canned asparagus products are utilized in salads, soups, as well as additives in meat or  
52 poultry dishes. Recent market predictions indicate that global consumption of asparagus is on an upward  
53 trend <sup>2</sup>.

54 Increased popularity of asparagus consumption could be attributed to it being a low caloric food  
55 with numerous bioactive compounds as well as due to better availability of asparagus on the market.  
56 Green asparagus has higher concentrations of bioactive compounds compared to less popular purple and  
57 white varieties of *A. officinalis* and is promoted as one of the healthier foods <sup>3</sup>. Saponins, phenolics,  
58 sterols, and flavonoids are considered the main groups of bioactive compounds in asparagus <sup>1</sup>. Among  
59 the commonly consumed vegetables, asparagus is among the top ranked with respect to its antioxidant  
60 properties. These are attributed to the presence of phenolic phytochemicals such as saponins, rutin, and  
61 protodioscin <sup>4</sup>. In addition, asparagus products also exert metal chelating properties, and 2"-

62 hydroxynicotianamine isolated from asparagus was shown to inhibit the activity of angiotensin-  
63 converting enzymes in the kidneys through metal chelation <sup>5</sup>. Asparagus also contains an appreciable  
64 amount of dietary fiber, mostly comprising fructans and inulins as well as hemicelluloses and pectins, all  
65 of which are not digestible by human oro-gastro-intestinal (OGI) enzymes and are thus available for  
66 fermentation by gut microbes <sup>6</sup>. Dietary fiber in asparagus extracts have shown hypoglycemic and  
67 hypotriglyceridemic properties, suggesting a potential use of asparagus in the management of diabetes <sup>7</sup>.  
68 In addition, asparagus and its products have also been used in medicinal applications due to its purported  
69 anti-neurotoxic properties (shown in rats) <sup>8</sup>, antitumor properties (shown *in vitro*) <sup>9</sup>, blood cholesterol  
70 regulation through bile acids binding (shown *in vitro*) <sup>10</sup>, and even as a treatment for insomnia in humans  
71 <sup>11</sup>.

72 Deviating from the traditional use, novel nutritional trends suggest incorporating dried asparagus  
73 powder into the diet. Asparagus moisture content varies in the different parts of the shoots, and this  
74 moisture is removed through various drying processes during the commercial production of asparagus  
75 powder <sup>1</sup>. Use of asparagus powder in meatloaf preparation has resulted in a novel meat product of high  
76 nutritive value, antioxidant activity, and sensory attractiveness <sup>12</sup>. Furthermore, fortification with  
77 asparagus powder has been shown to change the physiochemical parameters of cheese and improve its  
78 nutritional value <sup>13</sup>. Fiber extracts from asparagus have also been used to enrich yoghurts <sup>14</sup>.  
79 Furthermore, the incorporation of asparagus powder in value-added pasta preparations has improved the  
80 firmness, hardness, and protein and fiber content of such pasta <sup>15</sup>.

81 Many health benefits of asparagus are attributed to its nutritional composition, where dietary  
82 fiber and bioactive compounds such as polyphenols stand out as key contributors. The majority of these  
83 phytochemicals escape human OGI digestion and are available to colonic microbiota, which could  
84 ferment these compounds and also release bound polyphenols into the gut <sup>16</sup>. However, despite the  
85 importance of exploring the benefits of asparagus consumption with respect to gut health, there is little  
86 to no extensive work available on how asparagus is fermented by the gut microbiota. In this study, we  
87 investigated the OGI digestion and subsequent gut microbiota fermentation of green asparagus powder  
88 using the *in vitro* Human Gut Simulator system <sup>17</sup>.  
89

## 90 Materials and Methods

### 91 *In vitro digestion of asparagus powder.*

92 Dried asparagus powder from *Asparagus officinalis* (green asparagus) was obtained commercially  
93 (Nutricargo LLC, MI). The nutritional composition of asparagus powder was calculated based on the  
94 composition of fresh asparagus as 20 calories, 0.1 g total fats, 3.9 g total carbohydrates including 2.1 g

95 of dietary fiber, and 2.2 g of proteins per 100 grams as listed in the USDA FoodData Central database.  
96 These values were adjusted to reflect the content equivalent in dried asparagus powder with 5%  
97 moisture, as per industrial asparagus drying protocols. We carried out an *in vitro* digestion of dried  
98 asparagus powder designed to mimic the human OGI digestion of foods as was described previously<sup>18</sup>.  
99 Briefly, during the oral digestion phase, asparagus powder was mixed with simulated salivary fluid in  
100 1:2 ratio and maintained at 37 °C for 2 minutes at pH 7, to mimic human oral digestion conditions (see  
101 **Figure 1A**). Due to the high hygroscopic nature of the asparagus powder, the use of 1:2 ratio ensured  
102 the proper salivary digestion. The generated oral bolus was mixed in 1:1 ratio with the simulated gastric  
103 fluid and was maintained at 37 °C for 2 hours at pH 3. This process was equivalent to the human gastric  
104 digestion. Finally, the produced gastric chyme was mixed in 1:1 ratio with the simulated intestinal fluid  
105 and maintained at 37 °C for 2 hours at pH 7 to mimic the human intestinal digestion. This final mixture  
106 was centrifuged in 50-ml aliquots at 6,000 rpm, and supernatant and residues were collected,  
107 homogenized, and stored at -70 °C until further use. For enzymatic digestions, pepsin was purchased  
108 from Sigma-Aldrich (St Louis, MO), and the enzymatic assay was performed to determine the enzyme  
109 activity<sup>19</sup>. Amylase and pancreatin was purchased from MP Biomedicals (Irvine, CA), and the  
110 enzymatic activity values were provided by the manufacturer.

111

112 ***In vitro Human Gut Simulator (HGS) experiments.***

113 Gut microbial fermentation of the digested asparagus powder was carried out in the *in vitro* HGS  
114 system, which had been previously described and validated<sup>17</sup>. HGS is a fully anaerobic system  
115 comprised of five linked compartments: a medium reservoir, a proximal colon vessel, a transverse colon  
116 vessel, a distal colon vessel, and a waste collector. The compartments are connected via medium transfer  
117 tubes, and medium is transferred by automatically operated peristaltic pumps, which ensure  
118 unidirectional movement of contents mimicking the movement of a food bolus in the gut. The medium  
119 reservoir contains a nutrient medium that was designed to mimic the contents that reach the gut of an  
120 adult after digestion of Western pattern diet foods (called Western diet medium, or WM)<sup>17</sup>. At day 0,  
121 each vessel was inoculated with a homogenized fecal inoculum prepared from fresh fecal samples  
122 obtained from three healthy adults (male and female North Americans and male Western European; age  
123 range 24-43, BMI range 19.3-24.8). Donors were screened for the use of dietary supplements,  
124 antibiotics, and history of gastrointestinal diseases within six months prior to stool donation.

125 Each vessel was volume-, temperature-, and pH-regulated to match the conditions of its  
126 respective colonic region, and the contents were mixed continuously. The system was sparged twice  
127 daily with a mixture of N<sub>2</sub> and CO<sub>2</sub> gases to ensure anaerobicity. The system was operated continuously

128 for six weeks. Two replicate runs were performed, with each run comprising three different phases that  
129 differed in the composition of medium provided to the proximal vessel (**Table 1** and **Figure 1B**). In  
130 phase 1, western diet medium was provided for the first two weeks to establish a stable microbiota  
131 community in each region (day 0 to day 14: phase 1)<sup>18, 20</sup>. After two weeks, the medium reservoir was  
132 switched to supply the digested asparagus medium (denoted YEM+ASP, **Table 1**) for two more weeks  
133 (day 14 to day 28: phase 2). YEM+ASP contained the same salt concentrations as WM. However, all  
134 macronutrients of WM (with an exception of yeast extract required to provide vitamins and cofactors)  
135 were replaced by asparagus digest residue, which was added in equivalent amount (23.9 g l<sup>-1</sup>).  
136 Additionally, 10% of the digested asparagus supernatant was also added to represent the digested  
137 soluble compounds escaping absorption in the small intestine<sup>21</sup>. The yeast extract concentration was  
138 similar to WM, and mucin was not added to the YEM+ASP medium because addition of mucin during  
139 this phase would add additional nutrients that are not of asparagus origin. During this phase, members of  
140 the gut community that are capable of utilizing asparagus bioactive compounds along with syntrophic  
141 organisms were expected to thrive. After a further two weeks, the reservoir medium was changed to  
142 contain yeast extract medium (YEM) for the final two weeks (day 28 to day 42: phase 3). Compared to  
143 the YEM+ASP medium, YEM lacked both the asparagus digest as well as the supernatant, hence YEM  
144 provides limited amounts of nutrients, mainly through the yeast extract. Detailed nutrient constituents in  
145 each medium are provided in **Table 1**.

146 Throughout the HGS runs, multiple samples were taken as shown in **Figure 1B**, and cell  
147 densities were measured by phase contrast microscopy using a Spencer hemocytometer. Collected  
148 samples were centrifuged to separate them into cell pellets, which were used for bacterial genomic DNA  
149 isolation using ZR bacterial DNA isolation kit (Zymo Research), and the supernatants, which were used  
150 for short-chain fatty acid (SCFA) and antioxidant measurements. All samples were stored at -70 °C.  
151

### 152 *Microbiota composition analysis.*

153 Isolated bacterial genomic DNA was amplified in a PCR reaction targeting V4 hypervariable region of  
154 the 16S rRNA gene using degenerate forward (16S rRNA gene complementary sequence  
155 GCCAGCMGCCGCGG) and reverse (complementary sequence GGACTACHVGGGTWTCTAAT)  
156 primers<sup>20</sup>. PCR reaction consisted of 4 linear and 25 exponential cycles in order to reduce PCR  
157 amplification biases<sup>20, 22</sup>. Generated amplicons were sequenced on the Ion Torrent Personal Genome  
158 Machine using multiple Ion 318 and 316 chips (Thermo Fisher Scientific) as described previously<sup>23</sup>. We  
159 obtained an average of 20,916 sequence reads per sample after quality filtering (minimum 11,408,  
160 maximum 36,079). Reads were processed in QIIME<sup>24</sup> using our default pipeline, followed by the 16S

161 copy number adjustment<sup>20, 25</sup>. Taxon annotation was based on the Ribosomal Database Project  
162 Classifier v2.11 and RDP 16S rRNA training set 19. Cell counts of all samples were multiplied to match  
163 the cell density of each sample<sup>17</sup>, and this cell density adjusted dataset was used for all downstream  
164 analyses. Cumulative table of genus-level cell densities in all samples is provided in **Supplementary**  
165 **Table S1**.

166

167 ***Calculation of cumulative counts of beneficial and detrimental microbes.***

168 We employed our recently published approach<sup>21</sup> to estimate the total cell counts of microbial taxa  
169 considered to be either beneficial or detrimental to human health. Briefly, cell density adjusted taxon  
170 counts of predetermined beneficial and detrimental members were summed and their collective counts  
171 were expressed as the relative combined abundance of beneficial and detrimental taxa. Total beneficial  
172 microbes consisted of combined abundances (arithmetic sum) of *Akkermansia*, *Bifidobacterium*,  
173 *Eubacterium*, *Faecalibacterium*, *Lactobacillus*, *Roseburia*, and *Streptococcus*. Total detrimental  
174 microbes combined the abundances of *Clostridioles difficile*, Desulfovibrionaceae, Enterobacteriaceae,  
175 *Fusobacterium*, and *Helicobacter*.

176

177 ***Short-chain fatty acid measurements.***

178 The preparation of samples for the chromatographic analysis was performed by centrifuging  
179 fermentation supernatant samples at 13,300 rpm for 5 min, filtering them through a 0.22 µm pore size  
180 filter and performing a 1:10 dilution with 1M hydrochloric acid<sup>26</sup>. SCFAs were resolved by the HPLC  
181 analysis on the Agilent Poroshell 120 SB-Aq column (3 x 150 mm, 2.7 µm particle size). The mobile  
182 phase was 5 mM sulfuric acid with isocratic elution at a flow rate of 0.5 ml min<sup>-1</sup>. The injection volume  
183 was 5 µl. The column and detector temperature were set at 35 °C.

184 The chromatographic analysis was performed in duplicate for each sample. Quantification was  
185 carried out against calibration curves constructed for the following external standards: acetic, butyric,  
186 lactic, isovaleric, propionic, and succinic acids, in concentrations ranging from 0 to 100 mM. Results  
187 were expressed in mmol of each acid per liter (mM) of fermentation supernatant.

188

189 ***Antioxidant capacity measurements.***

190 Antioxidant capacity of samples was estimated using an ABTS assay adapted to a microplate reader  
191 (FLUOStar Omega, BMG Labtech) as we have done previously<sup>16</sup>. In the assay, 2,2'-azino-bis(3-  
192 ethylbenzothiazoline-6-sulfonic acid) diammonium salt (ABTS) is oxidized by potassium persulfate to  
193 form an ABTS-radical cation, which has a characteristic blue-green color. The assay measures the

194 antioxidant capacity of samples to prevent or revert back this oxidation in comparison with a Trolox  
195 standard. The reactions combined 280 µl of the working ABTS solution with 20 µl of a sample or Trolox  
196 standard in each well of a 96-well polystyrene plate, and the color development was measured  
197 spectrophotometrically in triplicates. The Trolox standard curve was constructed by using a range of  
198 Trolox concentrations between 0.01 and 0.1 mg ml<sup>-1</sup>, and the obtained results were expressed as mmol  
199 (Trolox equivalents) per liter of sample.

200

201 ***Epithelial cell culture experiments.***

202 Human colorectal cancer Caco-2 cells were received from ATCC (Catalog #HTB-37) and were  
203 maintained in DMEM medium (Gibco) supplemented with 10% fetal bovine serum (HyClone), 2 mM L-  
204 glutamine (GenDepot) and 1x penicillin/streptomycin mixture (Lonza) at 37 °C in 5% CO<sub>2</sub>. For  
205 experimental assays, 1x10<sup>5</sup> cells were seeded in the semipermeable supports (Corning Transwell, 12 mm  
206 diameter, 0.45 µm pore size). Cells were maintained for 21 days with replacement of fresh complete  
207 growth medium every two days to promote basolateral-apical differentiation. Differentiation was  
208 followed by measuring transepithelial electrical resistance (TEER, see below). After 21 days, cells were  
209 treated with 5% dextran sulfate sodium (DSS) alone or in combination with the following solutions:  
210 SCFA mixture, a WM-grown culture supernatant (day 14), an asparagus digest medium-grown culture  
211 supernatant (day 28), and a fresh non-fermented asparagus medium. Control wells contained complete  
212 growth medium without DSS. Supernatants and asparagus medium were provided in 1/10 concentrations  
213 to account for the expected metabolite gradient from the lumen to the epithelial surface<sup>27</sup>. SCFA  
214 mixture contained acetic, butyric, and propionic acids matching the measured concentrations of these  
215 acids in the diluted (1/10) asparagus digest medium. After applying treatments, wells were incubated at  
216 37 °C in 5% CO<sub>2</sub> for 24 hours. For each assay, we performed two independent experiments for each of  
217 the two HGS runs, each with duplicates. Out of two replicate wells, one was used for the MTS and  
218 TEER assays (see below), while the other well was used for RNA isolation. Thus, four replicate values  
219 were obtained for each measurement.

220 TEER assay measured the current across the epithelial layer and served to assess the epithelial  
221 barrier function. Transepithelial resistance was measured with an EVOM<sup>2</sup> instrument (World Precision  
222 Instruments) following manufacturer's instructions. To assess the effect of DSS treatment on epithelial  
223 barrier function, TEER measurements were recorded in all wells immediately before the treatments, and  
224 six and 24 hours after the treatment.

225 For the MTS assay, cells were trypsinized and counted after 24 h of treatment. A total of 5.0 x  
226 10<sup>4</sup> cells were added in triplicates along with fresh complete growth medium to a 96-well plate, and the

227 assay was carried out using the CellTiter AQueous Cell Proliferation Assay kit (Promega) following  
228 manufacturer's protocol. Colorimetric reaction development was measured after 1h and 3h of incubation  
229 at OD<sub>490nm</sub>.

230 To measure the expression of select cytokines in the treated epithelial cells, total RNA was  
231 isolated from harvested Caco-2 cells with the Quick-RNA Miniprep kit (Zymo Research) following  
232 manufacturer's protocol. cDNA was generated with the LunaScript RT Supermix (New England  
233 Biolabs), and SYBR Green based qPCR assays were run on ABI Prism 7000 Sequence Detection  
234 System using Luna Universal qPCR Mastermix (New England Biolabs) essentially as described<sup>28</sup>. The  
235 sequences of used qPCR primers are listed in the **Supplementary Table S2**. All qPCR tests were run in  
236 triplicate, and specificity of each amplification was assessed by the melting curve analysis of amplified  
237 samples. The expression of each profiled cytokine was normalized to the endogenous level of GAPDH  
238 reference<sup>29</sup>.

239

240 **Data analyses.**

241 All statistical and multivariate analyses were carried out in R, Python, and Matlab<sup>30</sup>. Multivariate  
242 ordination analyses included principal components analysis (PCA) and phylogenetic UniFrac distance-  
243 based principal coordinates analysis (UF-PCoA). Where shown, statistical significance of group  
244 separation in ordination space was based on the permutation of the Davies-Bouldin index as we  
245 described previously<sup>31</sup>. Logistic regression with Lasso regularization (C=1) was run in ORANGE to  
246 reveal genera statistically associated with WM and YEM+ASP microbial communities as we did  
247 previously<sup>29</sup>. PICRUSt2 and STAMP software were used to evaluate the predicted encoded functions of  
248 profiled microbial communities<sup>32</sup>. Statistical significance of the differential pathway abundances  
249 between groups was calculated with the Welch's t-test with Benjamini-Hochberg correction for multiple  
250 hypothesis testing<sup>33</sup>. Pathway was defined as differentially encoded (DE) if it was at least 1.5-fold more  
251 prominent in either WM or YEM+ASP communities at the  $\alpha \leq 0.01$  significance level. Unless stated  
252 otherwise, statistical significance of the differences in measured values among vessels or media was  
253 calculated with repeated measures ANOVA (RM ANOVA).

254

255 **Results**

256 ***Microbial fermentation of digested asparagus powder.***

257 Dried asparagus powder was first subjected to the three-step digestion procedure (shown in **Figure 1A**)  
258 designed to simulate the human oro-gastro-intestinal digestion. The HGS system was then used to carry  
259 out a three-phase cultivation of human gut microbiota following a procedure outlined in **Figure 1B**.

260 Western diet medium represented the food digest entering colon in a subject consuming a typical  
261 Western diet (relatively high in animal proteins and fats). In the second phase, the medium was switched  
262 to the basal yeast extract medium supplemented with digested asparagus powder. Phase three was a  
263 control medium only containing yeast extract, vitamins, and salts (see **Table 1**). This combination of  
264 three phases of HGS operation allowed us to (i) compare community fermentation of nutrients obtained  
265 from the western diet vs digested asparagus powder, and to (ii) separate the specific effects of ASP  
266 fermentation from those arising due to the lack of western diet nutrients.

267 Two independent runs showed a good concordance in community density levels and changes  
268 upon medium switches (**Figure 2A**). During phase 1 (days 0-14), cell densities in all three vessels  
269 increased gradually as the seeded communities adapted and maximized the use of WM components. The  
270 overall density decreased from proximal to transverse to distal vessels (see distal vessel panel of **Figure**  
271 **2A**), likely due to the diminishing nutrient availability as was observed in other HGS runs <sup>18, 20</sup>.  
272 Switching to YEM+ASP medium during phase 2 (days 15-28) lowered cell densities in all three vessels,  
273 suggesting a potential growth restriction of the ASP medium. Since the total amount of macronutrients  
274 was equal between the WM and YEM+ASP media, this reduction in cell density may be attributed to  
275 either (i) the poorer accessibility of nutrients in YEM+ASP or (ii) the previously documented presence  
276 of antimicrobial phytochemicals in asparagus including polyphenols, saponins, and alkaloids <sup>1</sup>.  
277 Interestingly, cell density in the transverse vessel gradually exceeded that of the proximal vessel during  
278 phase 2, consistent with the presence of a significant amount of dietary fiber in the YEM+ASP medium  
279 requiring longer fermentation times and thus providing more nutrients to the transverse vessel  
280 communities. Note that fresh medium is directly added to the proximal vessel only, which usually  
281 maintains the densest microbial communities due to higher nutrient availability <sup>18, 20</sup>. Hence, our  
282 observation presents a notable diet associated shift in the dominant colonic region of microbial activity.  
283 Switching to YEM during phase 3 (days 29-42) lowered the cell densities drastically across all three  
284 HGS vessels due to the limited nutritional value of YEM (**Figure 2A**).  
285

286 ***Asparagus fermentation causes a shift in microbial community structure.***

287 In contrast to the reduction in cell densities between WM and YEM+ASP cultures, community diversity  
288 increased upon this medium switch (**Figure 2B**). Community evenness was more comparable, only  
289 reaching the statistically significant increase in the proximal vessel. YEM communities had noticeably  
290 higher evenness in all three vessels, attributed to the reduction in the abundance of dominant community  
291 members in the nutrient-poor environment.

292 At the class level, WM and YEM+ASP communities were dominated by classes Clostridia,  
293 Bacteroidia, and Negativicutes (**Figure 2C**). Switching the supplied medium from WM to YEM+ASP  
294 led to a statistically significant reduction in cell counts of Negativicutes in the proximal vessel and  
295 Bacteroidia in the distal vessel; total Deltaproteobacteria increased instead on YEM+ASP in the  
296 proximal ( $p<0.04$ ) and distal ( $p=0.09$ ) vessels. Because class Deltaproteobacteria is known to house  
297 several detrimental members of human gut microbiota, we calculated the total counts of presumed  
298 beneficial and presumed detrimental members in each sample. As shown in **Figure 2D**, the counts of  
299 beneficial members were comparable between WM and YEM+ASP cultures; however, the numbers of  
300 potentially detrimental microbes were higher in cultures provided the digested asparagus powder. YEM  
301 medium shifted the beneficial-to-detrimental microbe ratio drastically towards the detrimental side.

302 At the genus level, microbiota abundances were less consistent across the three vessels.  
303 *Bacteroides*, *Faecalibacterium*, *Mitsuokella*, *Phocaeicola*, and *Ruminococcus* were overall the most  
304 abundant genera (see **Supplementary Table S1**). These differences were sufficiently large to separate  
305 samples in PCoA ordination space according to the supplied medium ( $p<0.001$ ) as shown in **Figure 3A**.

306 To identify the key members of microbial communities that were predictive of these medium-  
307 based differences in each vessel, we employed a logistic regression based discriminant analysis <sup>29</sup>. This  
308 analysis revealed microbial genera that were uniquely associated with a microbial community of each  
309 medium (**Figure 4** shows the top discriminating genera for WM and YEM+ASP media). The genera that  
310 were abundant on the Western pattern diet medium but were not competitive on the asparagus digest  
311 included *Mitsuokella* (class Negativicutes) in the proximal vessel, *Mitsuokella*, *Negativibacillus*, and  
312 *Eisenbergiella* (both Clostridia) in the transverse vessel, and *Negativibacillus*, *Eisenbergiella*, and  
313 phylotypes classified as *Ruminococcus2* (from family Lachnospiraceae in the class Clostridia) in the  
314 distal vessel. It is likely that these members of the gut community failed to utilize asparagus digest as a  
315 source of nutrients or survive using microbial cross-feeding during the YEM+ASP phase. It could also  
316 be speculated that these members might have been affected severely by asparagus phytochemicals as  
317 described above, compared to other members of the community, resulting in a significant reduction of  
318 their abundances (**Figure 4** top row panels).

319 Genera that showed significant expansion in the YEM+ASP environment included  
320 *Ruminococcus* from family Ruminococcaceae (class Clostridia) in the proximal vessel, *Hungatella*  
321 (class Clostridia), *Marseilla* (class Bacteroidia), *Bilophila*, *Desulfovibrio* (both from class  
322 *Deltaproteobacteria*), and unidentified members of family Lachnospiraceae in the transverse vessel, as  
323 well as *Bilophila* and *Beduinibacterium* (class Clostridia) in the distal vessel (**Figure 4** bottom row  
324 panels). Because the counts of all of these genera were only increased in the presence of asparagus

325 digest (they were low in both WM and YEM media, see **Figure 4**), their expansion was due to the  
326 presence of favored nutrients among the digested ASP components.

327  
328 ***Metabolite and antioxidant production vary among the growth media.***

329 We measured concentrations of six short-chain fatty acids - acetate, propionate, butyrate, isovalerate,  
330 lactate, and succinate – in all profiled HGS samples. As expected, acetate was the most abundant SCFA,  
331 followed by propionate and butyrate. The total amount of measured SCFAs as well as the concentrations  
332 of individual fatty acids were generally comparable between the WM and YEM+ASP cultures (see a  
333 heatmap in **Figure 3B**). The switch from the WM to YEM+ASP medium led to a modest reduction on  
334 the amount of produced SCFAs in the proximal vessel (from 66.3mM to 62.8mM), concomitant with an  
335 increase in production in the transverse vessel (from 64.0mM to 73.2mM). This observation is consistent  
336 with the higher cell densities measured in the transverse vessel during phase 2, suggesting a relatively  
337 high metabolism in transverse vessel on the YEM+ASP medium. For all three vessels, YEM showed a  
338 drastic reduction in the total SCFA production as expected due to the limited nutrient availability during  
339 phase 3 (average total SCFA concentrations of 15mM, 13mM and 16mM for proximal, transverse, and  
340 distal vessels, respectively). These similarities and differences were reflected in the distribution of  
341 samples in the SCFA concentration based PCA space (**Figure 3B**), with clear visible separation of YEM  
342 samples.

343 Antioxidant capacity increased from WM (average 3.1 mmol/L) to YEM+ASP (average 5.6  
344 mmol/L) across all three vessels, and YEM cultures had the lowest antioxidant capacity (average 1.9  
345 mmol/L) (**Figure 3C**). This observation of increased antioxidant capacity due to asparagus fermentation  
346 is also confirmed by previous studies that found asparagus to possess significant antioxidant properties  
347 <sup>34</sup>. Antioxidant concentration of the freshly prepared YEM+ASP medium was 2.0 mmol/L on average,  
348 indicating that microbial fermentation led to a 2.8-fold increase in the available antioxidants ( $p < 0.005$   
349 for each vessel based on the two-sample T-test).

350  
351 ***Predicted functional capacities separate WM and YEM+ASP communities.***

352 By using the PICRUSt2 algorithm, we estimated the functional repertoire of community genomes in all  
353 profiled samples. These repertoires were sufficiently distinct to separate the WM, YEM+ASP, and YEM  
354 sample groups in the PCA ordination space with statistical significance (**Figure 5A**), and a number of  
355 differentially encoded pathways were revealed (**Figure 5B**). The relative abundances of several  
356 prominent pathways that differed between WM and YEM+ASP samples are displayed in **Figure 5C**.

357 Overall, the Western pattern diet medium supported fermentation pathways and the flux through  
358 the TCA cycle. The latter observation is possibly due to the higher amount of total fats in the WM  
359 providing higher availability of acetate. Inorganic metabolism and cofactor biosynthesis genes were  
360 encoded more frequently in the asparagus digest-grown cultures, consistent with the increase in  
361 *Desulfovibrio* abundance in these samples and likely associated with the presence of inorganic electron  
362 acceptors such as sulfate in asparagus<sup>35</sup>. Elevated capacity for methionine biosynthesis in asparagus-  
363 grown cultures (**Figure 5C**) might be attributed to the higher sulfurylation activity due to the presence of  
364 sulfur-containing compounds in asparagus<sup>36</sup>. This is corroborated by the increased abundance of the  
365 members of Deltaproteobacteria and Clostridia, both of which have been shown to contain genes for  
366 sulfurylation enzymes<sup>36</sup>.

367 It has been previously observed that flavonoids and polyphenols can directly interact with cell  
368 wall peptidoglycans and inhibit the growth of certain bacteria including *Escherichia coli*, *Pseudomonas*  
369 *fluorescens*, and *Staphylococcus aureus*<sup>37</sup>. The high concentration of polyphenols and flavonoids in  
370 asparagus could thus be expected to elicit a similar effect, resulting in the reduction of predicted  
371 repertoire of peptidoglycan maturation genes observed during asparagus fermentation.

372  
373 ***Supernatant from fermented asparagus cultures protects epithelial cells against DSS-induced damage***  
374 ***and inflammation.***

375 DSS treatment has been used in many *in vivo* and *in vitro* studies to simulate epithelial damage often  
376 observed in irritable bowel disease (IBD) and other gastrointestinal illnesses<sup>38-40</sup>. To assess whether  
377 microbiota-fermented asparagus might protect gut tissues against injury or inflammation, differentiated  
378 Caco-2 colorectal epithelial cancer cells were subjected to such DSS treatment alone or in combination  
379 with culture supernatants from select WM and YEM+ASP samples. A combination of acetate, butyrate,  
380 and propionate (ABP) in concentrations matching those measured in the YEM+ASP supernatant was  
381 used as a control. As can be observed in **Figure 6**, DSS addition to the apical side of Caco-2 layers led  
382 to a reduction in cell metabolic activity and epithelial barrier integrity (**Figure 6** panels **A** and **B**,  
383 respectively). Concurrent administration of culture supernatants from YEM+ASP samples (day 28) but  
384 not from WM samples (day 14) significantly reduced the deleterious effect of DSS on the epithelial  
385 cells. Similar protective effects were also observed for the fresh digested asparagus medium and ABP  
386 SCFA combination. While the metabolic activity in cells supplemented with DSS + day 28 supernatant,  
387 DSS + ASP medium, and DSS + ABP SCFAs treated Caco-2 samples did not differ from that of the  
388 control samples (**Figure 6A**), cell layer integrity was still reduced, but to a significantly lower extent  
389 when compared with the DSS only-treated cells (**Figure 6B**).

390 DSS has been shown previously to elevate the expression of several pro-inflammatory cytokines  
391 including IL-6, IL-10, IL-12, TNF $\alpha$ , and IFN $\gamma$ , while sometime also being able to increase the  
392 expression of anti-inflammatory TGF $\beta$ <sup>39, 41, 42</sup>. We therefore measured the mRNA expression of IL-6,  
393 IL-12A, TNF $\alpha$ , and TGF $\beta$ 2 variant genes in the control and treated Caco-2 cells. In our differentiated  
394 Caco-2 layers, DSS administration elevated the mRNA expression of IL-6, IL-12, and TNF $\alpha$  (**Figure 6C**). Co-administration of day 28 supernatants (YEM+ASP cultures) protected against DSS-increased  
395 expression of IL-6 and IL-12, but did not have an effect on the TNF $\alpha$  levels. In comparison, WM  
396 supernatants had a smaller positive effect on IL-6 and IL-12 expression and further increased TNF $\alpha$   
397 mRNA levels. While DSS treatment alone had no effect on the mRNA expression of TGF $\beta$  variant in  
398 our Caco-2 system, addition of both day 14 and day 28 supernatants significantly elevated the  
399 expression of this anti-inflammatory mediator (see **Figure 6C**).  
400

401

## 402 **Discussion and Conclusions**

403 In this study we investigated the changes of the gut microbial communities and metabolite production  
404 upon fermentation of digested asparagus. Overall, the revealed evidence pointed to the efficient  
405 fermentation of asparagus by human gut microbiota, with similar production of short chain fatty acids,  
406 fermentation end-products, in comparison with communities maintained on the Western pattern diet  
407 medium (see **Figure 3B**). Sole fermentation of asparagus could alter human gut microbiota community  
408 structure and change SCFA and antioxidant profiles. The highest SCFA production shifted on the  
409 YEM+ASP medium from the proximal to the transverse vessel, indicating that more time was needed to  
410 ferment asparagus components in comparison with WM. Antioxidant capacity was also increased on the  
411 YEM+ASP medium in all three vessels (see **Figure 3C**), attributed to the effect of microbial  
412 transformation of asparagus components (an average 2.8-fold increase in the available antioxidants after  
413 fermentation of the YEM+ASP medium).

414

415 While many members of gut microbiota adapted to asparagus fermentation with minimal  
416 changes, some members were positively or negatively influenced by the switch from the WM to  
417 YEM+ASP medium (see **Figure 4**). Asparagus promoted a significant expansion of *Ruminococcus* in  
418 the proximal vessel, a key genus of mammalian gut with well-known capabilities to degrade complex  
419 polysaccharides<sup>43</sup>, an observation in line with the complexity of asparagus phytochemicals. Previous  
420 studies have shown that the abundance of *Ruminococcus* was positively correlated with lower  
421 endotoxemia and lower BMI<sup>44</sup>, and members of this genus are able to elicit either pro- or anti-  
422 inflammatory effects based on the specific strain and the host physiology<sup>43</sup>. However, we also observed  
423 that asparagus fermentation favored the growth of sulfur-reducing members of the gut community

423 including *Bilophila* and *Desulfovibrio*. Members of these genera (e.g., *B. wadsworthia*, *D. piger*, and *D.*  
424 *desulfuricans*) can utilize sulfur containing compounds to produce H<sub>2</sub>S and are generally considered  
425 detrimental to human health <sup>45</sup>. Asparagus is rich in sulfur containing compounds including asparagusic  
426 acid and asparaptine <sup>2,46</sup>. It is likely that the presence of these molecules led to an increased availability  
427 of sulfur-rich compounds in the YEM+ASP medium, and they are subsequently metabolized by the  
428 sulfate-reducing bacteria in the anaerobic environment. In line with this, pathways of assimilatory  
429 sulfate reduction were encoded more frequently in the YEM+ASP communities (see **Figure 5C**). H<sub>2</sub>S  
430 production by human microbiota has been associated with several ill effects such as colonic  
431 inflammation and cancer, though some recent studies have attested to the protective role of H<sub>2</sub>S against  
432 oxidative stress in the gut mucosa <sup>47</sup>.

433 Our most intriguing finding was uncovering the protective role of fermented asparagus  
434 supernatant against a DSS-induced epithelial injury (see **Figure 6**). Both the cell metabolic activity and  
435 epithelial barrier function were less affected by DSS stressor in the presence of YEM+ASP supernatant.  
436 This effect was stronger for YEM+ASP supernatant than that for the addition of (i) fermented WM  
437 supernatant, (ii) fresh unfermented asparagus medium, or (iii) the solution of ABP short-chain fatty  
438 acids, possibly due to the elevated presence of antioxidants in the YEM+ASP medium <sup>48</sup>. Furthermore,  
439 YEM+ASP supernatant also reduced the DSS-induced expression of pro-inflammatory cytokines IL-6  
440 and IL-12, while it increased the expression of anti-inflammatory TGF $\beta$  (see **Figure 6C**).

441 In conclusion, we present the first evidence of human gut microbial fermentation of raw  
442 asparagus. The beneficial effects of asparagus fermentation included an increase in antioxidant capacity,  
443 maintenance of SCFA production, and protection against epithelial injury and inflammation. The  
444 combination of these effects is expected to outweigh any potential negative outcome induced by the H<sub>2</sub>S  
445 production.

446

#### 447 **Supplementary Materials**

448 **Supplementary Table S1:** cumulative genus-level cell densities in all samples.

449 **Supplementary Table S2:** sequences of qPCR primers used in this study.

450

#### 451 **Acknowledgements**

452 We are thankful to Michael Bottomley and Shamvabi Jha (both at Wright State University) for valuable  
453 comments. Work in O.P. laboratory was supported in part by NSF award DBI-1335772 and by Uprising  
454 Foods, Inc.

455

456 **Author Contributions**

457 Conceptualization, S.R. and O.P.; Methodology, S.R., B.B., B.N.P., D.R.C., and O.P.; Validation, B.B.,  
458 S.P.B., and D.R.C.; Formal Analysis, S.R., and O.P.; Data Curation, S.R., S.P.B., and O.P.; Writing,  
459 S.R. and O.P.; Supervision, J.A.R.H., K.J.C., and O.P.; Project Administration, O.P.; Funding  
460 Acquisition, O.P.

461

462 **Conflicts of Interest**

463 The authors declare no conflict of interest.

464

465 **References**

466

1. Q. Guo, N. Wang, H. Liu, Z. Li, L. Lu and C. Wang, The bioactive compounds and biological functions of *Asparagus officinalis* L. – A review, *Journal of Functional Foods*, 2020, **65**, 103727.
2. E. Pegiou, R. Mumm, P. Acharya, R. C. H. de Vos and R. D. Hall, Green and White Asparagus (*Asparagus officinalis*): A Source of Developmental, Chemical and Urinary Intrigue, *Metabolites*, 2020, **10**, 17.
3. J. Kobus-Cisowska, D. Szymanowska, O. M. Szczepaniak, A. Gramza-Michałowska, D. Kmiecik, B. Kulczyński, P. Szulc and P. Góraś, Composition of polyphenols of asparagus spears (*Asparagus officinalis*) and their antioxidant potential, *Ciência Rural*, 2019, **49**, e20180863.
4. Y.-P. Guo, L. Shao, M.-Y. Chen, R.-F. Qiao, W. Zhang, J.-B. Yuan and W.-H. Huang, In Vivo Metabolic Profiles of *Panax notoginseng* Saponins Mediated by Gut Microbiota in Rats, *Journal of agricultural and food chemistry*, 2020, **68**, 6835-6844.
5. M. Sanae and A. Yasuo, Green Asparagus (*Asparagus officinalis*) Prevented Hypertension by an Inhibitory Effect on Angiotensin-Converting Enzyme Activity in the Kidney of Spontaneously Hypertensive Rats, *Journal of agricultural and food chemistry*, 2013, **61**, 5520-5525.
6. A. Redondo-Cuenca, A. García-Alonso, R. Rodríguez-Arcos, I. Castro, C. Alba, J. Miguel Rodríguez and I. Goñi, Nutritional composition of green asparagus (*Asparagus officinalis* L.), edible part and by-products, and assessment of their effect on the growth of human gut-associated bacteria, *Food Research International*, 2023, **163**, 112284.
7. J. Zhao, W. Zhang, X. Zhu, D. Zhao, K. Wang, R. Wang and W. Qu, The aqueous extract of *Asparagus officinalis* L. by-product exerts hypoglycaemic activity in streptozotocin-induced diabetic rats, *Journal of the science of food and agriculture*, 2011, **91**, 2095-2099.
8. F. G. Elsaied, A. A. Shati and M. A. Sarhan, Role of *Matricaria recutita* L. and *Asparagus officinalis* L. against the neurotoxicity of diazinon in rats, *The Journal of Basic & Applied Zoology*, 2015, **72**, 26-35.
9. S. A. Sullivan, A. Q. M. Tran, G. Xu, Y. Yin, C. Zhou and V. L. Bae-Jump, Asparagus polysaccharide inhibits cell proliferation, adhesion and invasion in endometrial cancer cells, *Gynecologic Oncology*, 2017, **145**, 133.

496 10. T. S. Kahlon, M. H. Chapman and G. E. Smith, In vitro binding of bile acids by okra, beets,  
497 asparagus, eggplant, turnips, green beans, carrots, and cauliflower, *Food Chemistry*, 2007, **103**,  
498 676-680.

499 11. Y. Huang, Q. Zhou, J. An, W. Cai and W. Lyu, Effect of Instant Asparagus Powder on Sleeping  
500 Disorder, *Agricultural Science & Technology*, 2017, **18**, 975-978,1001.

501 12. J. Kobus-Cisowska, E. Flaczyk, D. Kmiecik, A. Gramza-Michalowska, B. Kulczynski and P.  
502 Juszczak, Applicability of asparagus (*Asparagus officinalis L.*) as a component of meatloaf,  
503 *Nauka Przyroda Technologie. Uniwersytet Przyrodniczy w Poznaniu*, 2017, **11**, 87-96.

504 13. P. Solhi, S. Azadmard-Damirchi, J. Hesari and H. Hamishehkar, Effect of fortification with  
505 asparagus powder on the qualitative properties of processed cheese, *Int J Dairy Technol*, 2020,  
506 **73**, 226-233.

507 14. T. Sanz, A. Salvador, A. Jiménez and S. M. Fiszman, Yogurt enrichment with functional  
508 asparagus fibre. Effect of fibre extraction method on rheological properties, colour, and sensory  
509 acceptance, *European Food Research and Technology*, 2008, **227**, 1515-1521.

510 15. A. C. P. Vital, C. Itoda, Y. S. Crepaldi, B. R. Saraiva and P. T. Matumoto-Pintro, Use of  
511 asparagus flour from non-commercial plants (residue) for functional pasta production: Asparagus  
512 flour for functional pasta production, *Journal of food science and technology*, 2020, **57**, 2926-  
513 2933.

514 16. S. Pérez-Burillo, S. Rajakaruna, S. Pastoriza, O. Paliy and J. Ángel Rufián-Henares, Bioactivity  
515 of food melanoidins is mediated by gut microbiota, *Food Chem*, 2020, **316**, 126309.

516 17. R. Agans, A. Gordon, D. L. Kramer, S. Perez-Burillo, J. A. Rufian-Henares and O. Paliy, Dietary  
517 Fatty Acids Sustain the Growth of the Human Gut Microbiota, *Appl Environ Microbiol*, 2018,  
518 **84**, e01525-01518.

519 18. K. L. Sprague, S. Rajakaruna, B. Bandow, N. Burchat, M. Bottomley, H. Sampath and O. Paliy,  
520 Gut Microbiota Fermentation of Digested Almond–Psyllium–Flax Seed-Based Artisan Bread  
521 Promotes Mediterranean Diet-Resembling Microbial Community, *Microorganisms*, 2024, **12**,  
522 1189.

523 19. A. Brodkorb, L. Egger, M. Alminger, P. Alvito, R. Assunção, S. Ballance, T. Bohn, C. Bourlieu-  
524 Lacanal, R. Boutrou, F. Carrière, A. Clemente, M. Corredig, D. Dupont, C. Dufour, C. Edwards,  
525 M. Golding, S. Karakaya, B. Kirkhus, S. Le Feunteun, U. Lesmes, A. Macierzanka, A. R.  
526 Mackie, C. Martins, S. Marze, D. J. McClements, O. Ménard, M. Minekus, R. Portmann, C. N.  
527 Santos, I. Souchon, R. P. Singh, G. E. Vegarud, M. S. J. Wickham, W. Weitschies and I. Recio,  
528 INFOGEST static in vitro simulation of gastrointestinal food digestion, *Nat Protoc*, 2019, **14**,  
529 991-1014.

530 20. S. Rajakaruna, S. Pérez-Burillo, D. L. Kramer, J. Á. Rufián-Henares and O. Paliy, Dietary  
531 Melanoidins from Biscuits and Bread Crust Alter the Structure and Short-Chain Fatty Acid  
532 Production of Human Gut Microbiota, *Microorganisms*, 2022, **10**, 1268.

533 21. S. Rajakaruna, S. Pérez-Burillo, J. Á. Rufián-Henares and O. Paliy, Human gut microbiota  
534 fermentation of cooked eggplant, garlic, and onion supports distinct microbial communities,  
535 *Food & Function*, 2024, **15**, 2751-2759.

536 22. M. F. Polz and C. M. Cavanaugh, Bias in template-to-product ratios in multitemplate PCR, *Appl  
537 Environ Microbiol*, 1998, **64**, 3724-3730.

538 23. S. Perez-Burillo, T. Mehta, A. Esteban-Munoz, S. Pastoriza, O. Paliy and J. Angel Rufian-  
539 Henares, Effect of in vitro digestion-fermentation on green and roasted coffee bioactivity: The  
540 role of the gut microbiota, *Food Chem*, 2019, **279**, 252-259.

541 24. J. G. Caporaso, J. Kuczynski, J. Stombaugh, K. Bittinger, F. D. Bushman, E. K. Costello, N.  
542 Fierer, A. G. Pena, J. K. Goodrich, J. I. Gordon, G. A. Huttley, S. T. Kelley, D. Knights, J. E.  
543 Koenig, R. E. Ley, C. A. Lozupone, D. McDonald, B. D. Muegge, M. Pirrung, J. Reeder, J. R.  
544 Sevinsky, P. J. Turnbaugh, W. A. Walters, J. Widmann, T. Yatsunenko, J. Zaneveld and R.  
545 Knight, QIIME allows analysis of high-throughput community sequencing data, *Nat Methods*,  
546 2010, **7**, 335-336.

547 25. S. Rajakaruna, D. A. Freedman, A. R. Sehgal, X. Bui and O. Paliy, Diet quality and body mass  
548 indices show opposite associations with distal gut microbiota in a low-income cohort, *J. Food  
549 Sci. Technol.*, 2019, **4**, 846-851.

550 26. A. Delgado-Osorio, B. Navajas-Porras, S. Pérez-Burillo, D. Hinojosa-Nogueira, Á. Toledano-  
551 Marín, S. Pastoriza de la Cueva, O. Paliy and J. Á. Rufián-Henares, Cultivar and Harvest Time  
552 of Almonds Affect Their Antioxidant and Nutritional Profile through Gut Microbiota  
553 Modifications, *Antioxidants*, 2024, **13**, 84.

554 27. P. R. Kiela and F. K. Ghishan, Physiology of Intestinal Absorption and Secretion, *Best Practice  
& Research Clinical Gastroenterology*, 2016, **30**, 145-159.

556 28. L. Rigsbee, R. Agans, V. Shankar, H. Kenche, H. J. Khamis, S. Michail and O. Paliy,  
557 Quantitative profiling of gut microbiota of children with diarrhea-predominant Irritable Bowel  
558 Syndrome, *Am J Gastroenterol*, 2012, **107**, 1740-1751.

559 29. M. P. Craig, S. Rajakaruna, O. Paliy, M. Sajjad, S. Madhavan, N. Reddy, J. Zhang, M.  
560 Bottomley, S. Agrawal and M. P. Kadakia, Differential MicroRNA Signatures in the  
561 Pathogenesis of Barrett's Esophagus, *Clin Transl Gastroenterol*, 2020, **11**, e00125.

562 30. O. Paliy and V. Shankar, Application of multivariate statistical techniques in microbial ecology,  
563 *Mol Ecol*, 2016, **25**, 1032-1057.

564 31. V. Shankar, D. Homer, L. Rigsbee, H. J. Khamis, S. Michail, M. Raymer, N. V. Reo and O.  
565 Paliy, The networks of human gut microbe-metabolite associations are different between health  
566 and irritable bowel syndrome, *Isme J*, 2015, **9**, 1899-1903.

567 32. G. M. Douglas, V. J. Maffei, J. R. Zaneveld, S. N. Yurgel, J. R. Brown, C. M. Taylor, C.  
568 Huttenhower and M. G. I. Langille, PICRUSt2 for prediction of metagenome functions, *Nature  
569 biotechnology*, 2020, **38**, 685-688.

570 33. Y. Benjamini and Y. Hochberg, Controlling the False Discovery Rate - a practical and powerful  
571 approach to multiple testing, *J Roy Stat Soc B Met*, 1995, **57**, 289-300.

572 34. J. W. Lee, J. H. Lee, I. H. Yu, S. Gorinstein, J. H. Bae and Y. G. Ku, Bioactive Compounds,  
573 Antioxidant and Binding Activities and Spear Yield of Asparagus officinalis L, *Plant Foods for  
574 Human Nutrition*, 2014, **69**, 175-181.

575 35. Y. Matsubayashi and Y. Sakagami, Phytosulfokine, sulfated peptides that induce the  
576 proliferation of single mesophyll cells of Asparagus officinalis L, *Proceedings of the National  
577 Academy of Sciences*, 1996, **93**, 7623-7627.

578 36. M. P. Ferla and W. M. Patrick, Bacterial methionine biosynthesis, *Microbiology*, 2014, **160**,  
579 1571-1584.

580 37. M. Makarewicz, I. Drożdż, T. Tarko and A. Duda-Chodak, The Interactions between  
 581 Polyphenols and Microorganisms, Especially Gut Microbiota, *Antioxidants*, 2021, **10**, 188.

582 38. B. Chassaing, J. D. Aitken, M. Malleshappa and M. Vijay-Kumar, Dextran sulfate sodium  
 583 (DSS)-induced colitis in mice, *Curr Protoc Immunol*, 2014, **104**, 15.25.11-14.

584 39. Y. Araki, H. Sugihara and T. Hattori, In vitro effects of dextran sulfate sodium on a Caco-2 cell  
 585 line and plausible mechanisms for dextran sulfate sodium-induced colitis, *Oncol Rep*, 2006, **16**,  
 586 1357-1362.

587 40. M. Roselli, A. Maruszak, R. Grimaldi, L. Harthoorn and A. Finamore, Galactooligosaccharide  
 588 Treatment Alleviates DSS-Induced Colonic Inflammation in Caco-2 Cell Model, *Frontiers in*  
 589 *Nutrition*, 2022, **9**.

590 41. P. Alex, N. C. Zachos, T. Nguyen, L. Gonzales, T. E. Chen, L. S. Conklin, M. Centola and X. Li,  
 591 Distinct cytokine patterns identified from multiplex profiles of murine DSS and TNBS-induced  
 592 colitis, *Inflammatory bowel diseases*, 2009, **15**, 341-352.

593 42. M. Toutounji, D. Wanes, M. El-Harakeh, M. El-Sabban, S. Rizk and H. Y. Naim, Dextran  
 594 Sodium Sulfate-Induced Impairment of Protein Trafficking and Alterations in Membrane  
 595 Composition in Intestinal Caco-2 Cell Line, *International Journal of Molecular Sciences*, 2020,  
 596 **21**, 2726.

597 43. E. H. Crost, E. Coletto, A. Bell and N. Juge, Ruminococcus gnatus: friend or foe for human  
 598 health, *FEMS Microbiology Reviews*, 2023, **47**, 1-23.

599 44. F. Salas-Perez, T. S. Assmann, O. Ramos-Lopez, J. A. Martínez, J. I. Rieu-Boj and F. I.  
 600 Milagro, Crosstalk between Gut Microbiota and Epigenetic Markers in Obesity Development:  
 601 Relationship between Ruminococcus, BMI, and MACROD2/SEL1L2 Methylation, *Nutrients*,  
 602 2023, **15**, 1550.

603 45. S. B. Singh, A. Carroll-Portillo and H. C. Lin, Desulfovibrio in the Gut: The Enemy within?,  
 604 *Microorganisms*, 2023, **11**, 1772.

605 46. S. C. Mitchell and R. H. Waring, Asparagusic acid, *Phytochemistry*, 2014, **97**, 5-10.

606 47. D. Yonezawa, F. Sekiguchi, M. Miyamoto, E. Taniguchi, M. Honjo, T. Masuko, H. Nishikawa  
 607 and A. Kawabata, A protective role of hydrogen sulfide against oxidative stress in rat gastric  
 608 mucosal epithelium, *Toxicology*, 2007, **241**, 11-18.

609 48. J. Su, X. Zhang, Q. Kan and X. Chu, Antioxidant Activity of Acanthopanax senticosus  
 610 Flavonoids in H2O2-Induced RAW 264.7 Cells and DSS-Induced Colitis in Mice, *Molecules*,  
 611 2022, **27**, 2872.

612 49. R. Caspi, R. Billington, I. M. Keseler, A. Kothari, M. Krummenacker, P. E. Midford, W. K. Ong,  
 613 S. Paley, P. Subhraveti and P. D. Karp, The MetaCyc database of metabolic pathways and  
 614 enzymes - a 2019 update, *Nucleic acids research*, 2020, **48**, D445-453.

615  
 616 **Tables**

617  
 618 **Table 1. Medium composition, g l<sup>-1</sup>**

Medium component	WM *	YEM + ASP *	YEM *
------------------	------	-------------	-------

<i>Digested asparagus powder</i>			
Pellet (dry residue) <sup>†</sup>	-	23.9	-
Digest supernatant <sup>‡</sup>	-	29.7	-
<i>Carbohydrates</i>			
Arabinogalactan	1.8	-	-
Guar gum	0.9	-	-
Inulin	0.9	-	-
Pectin	1.8	-	-
Starch	4.4	-	-
Xylan	0.9	-	-
Cellobiose	0.9	-	-
Glucose	0.5	-	-
Fructose	0.5	-	-
<i>Proteins</i>			
Peptone	3.3	-	-
Casein	2.0	-	-
<i>Lipids</i>			
Palmitic acid	1.5	-	-
Stearic acid	0.8		
<i>Mucin</i>	4.0	-	-
<i>Yeast extract</i>	3.0	3.0	3.0
<i>Vitamins</i>	1.0	1.0	1.0
<i>Salts, other components</i>	14.1	14.1	14.1
Bile salts	0.2	0.2 <sup>**</sup>	0.1
Pancreatin	0.1	0.1 <sup>**</sup>	0.1

619

620 \* WM – Western pattern diet medium, YEM+ASP – digested asparagus based medium, YEM – yeast  
 621 extract medium

622 <sup>†</sup> Calculated wet weight equivalent: 145.8 g per liter of the medium

623 <sup>‡</sup> Wet weight, represents 10% of the total digestion supernatant

624 <sup>\*\*</sup> Amounts added during oro-gastro-intestinal digestion

625

626

627 **Figure legends**

628

629 **Figure 1. Experimental design.** Panel **(A)** depicts the steps of the *in vitro* oro-gastro-intestinal  
630 digestion of asparagus powder. Panel **(B)** visualizes longitudinal design of the *in vitro* Human Gut  
631 Simulator runs. Sample collection time points are indicated by a sample tube, and the analyses that were  
632 performed on each collected sample are listed. The medium was switched from a standard Western diet  
633 medium (WM) to the asparagus digest mixed with yeast extract and salts (YEM+ASP) after taking  
634 samples at the end of day 14, and then again to the yeast extract medium (YEM) at the end of day 28.

635

636 **Figure 2. Dynamic changes in community density and composition.** Different columns represent data  
637 for the three consecutively linked vessels simulating proximal, transverse, and distal colon as shown.  
638 Panel **(A)** displays the cell density in each vessel. Panel **(B)** visualizes the calculated average community  
639 diversity and evenness in the profiled samples as shown. Panel **(C)** shows the cumulative cell density of  
640 different microbial classes at each time point; each column represents the average class density among  
641 two replicate runs. Classes are grouped by their phylum assignment. Stars denote classes that had  
642 statistically significant differential abundance between WM and YEM+ASP samples; \*\*:  $p < 0.01$ , \*:  $p$   
643  $< 0.05$  (RM ANOVA). Combined relative abundances of the designated beneficial and detrimental  
644 microbes are plotted in panel **(D)**. Where shown, error bars represent the standard error of the mean  
645 ( $n=2$ ), and statistical significance between WM and YEM+ASP samples is presented for comparisons  
646 exceeding the  $\alpha=0.05$  level. The differences between WM/YEM+ASP and YEM communities were not  
647 statistically tested.

648

649 **Figure 3. Analysis of microbial community composition and activity.** Panel **(A)** displays the output  
650 of the unconstrained weighted UniFrac distance-based principal coordinates analysis (UF-PCoA) of the  
651 genus abundance dataset. Panel **(B)** visualizes the concentrations of measured short-chain fatty acids in  
652 all samples. In a heatmap, each column represents an average concentration of a particular acid among  
653 the two replicate runs. PCA ordination analysis of the SCFA concentration dataset is shown on the right  
654 side of panel **(B)**. The percent of dataset variability explained by each axis in PCoA and PCA analyses is  
655 shown in parentheses in axis titles. P values indicate the significance of group separation, NS - not  
656 significant at the  $\alpha=0.05$  level. Panel **(C)** displays the changes in the average antioxidant capacity of  
657 cultures over time. Error bars represent the standard error of the mean ( $n=2$ ).

658

659 **Figure 4. Changes in the cell densities of genera discriminating WM and YEM+ASP communities.**

660 Discriminating genera were determined with logistic regression based discriminant analysis. Top row  
661 displays changes in the average abundance of WM-discriminating genera in each vessel over time;  
662 bottom row shows YEM+ASP discriminating genera. Note the differences in the Y axis scale among  
663 panels and the break in the scale in top middle panel. Error bars represent the standard error of the mean  
664 (n=2).

665

666 **Figure 5. Analysis of predicted functional capacities of microbial communities.** Panel (A) visualizes  
667 the distribution of samples in the PCA ordination space based on the abundances of predicted  
668 metagenome-encoded microbial functions. The percent of dataset variability explained by each axis is  
669 shown in parentheses in axis titles. Panel (B) displays the numbers of statistically differentially encoded  
670 (DE) pathways in the predicted metagenomes of the WM and YEM+bread maintained communities.  
671 Predicted functional genes were assigned to pathways and pathway groups based on MetaCyc database  
672 <sup>49</sup>. Only pathway groups with at least two DE pathways are shown. The relative prevalence of several  
673 such pathways among WM and YEM+ASP samples is shown in panel (C) as box-and-whisker plots. P  
674 values represent statistical significance (Welch's t-test) of the difference in pathway fraction between  
675 WM and YEM+ASP sample sets.

676

677 **Figure 6. Effect of HGS culture supernatant and YEM+ASP medium on epithelial cell lines.** After  
678 differentiation on trans-well membrane support, confluent Caco-2 cell layers were subjected to the  
679 addition of DSS alone or in combination with either a mix of pure short-chain fatty acids (SCFAs),  
680 freshly prepared YEM+ASP medium, or supernatants (SN) from HGS cultures grown on WM (samples  
681 from proximal vessel taken on day 14) or YEM+ASP (day 28) media. Control columns represent Caco-2  
682 cells without any treatment. Panel (A) visualizes the epithelial cell metabolic activity in cells 24 hours  
683 after treatments as measured by the MTS assay after one and three hours of incubation. Panel (B)  
684 displays changes in epithelial layer integrity six and 24 hours post-treatment in comparison to pre-  
685 treatment values as measured by the TEER assay. Each column represents an average value among four  
686 tests (samples from two runs ran in duplicate), and error bar shows the standard error of the mean (n=4).  
687 Statistical significance was determined with paired-samples one-tail T test. In panel (B), all DSS treated  
688 samples reduced epithelial integrity compared to the changes in the control wells ( $p < 0.01$ , denoted with  
689 \*\*). Panel (C) shows the changes in the expression level of select inflammatory cytokines in Caco-2  
690 cells 24 hours after treatments in comparison with the control wells. Shown values represent expression

691 ratios between average  $\Delta Ct$  scores in the treated and control samples (n=3 in each set); error bars  
692 represent the standard error of the mean. Statistical significance of the differences was tested with the  
693 two-tail T-test at the  $\alpha=0.05$  level and the significant values are displayed.

The data supporting this article have been included as part of the Supplementary Information.




Figure 1

172x49mm (300 x 300 DPI)



Figure 2

172x171mm (300 x 300 DPI)




Figure 3

172x50mm (300 x 300 DPI)




Figure 4

172x54mm (300 x 300 DPI)




Figure 5

172x50mm (300 x 300 DPI)




Figure 6

172x37mm (300 x 300 DPI)